To assess, among premature infants with early respiratory distress syndrome (RDS), the effect of one dose of intratracheally administered surfactant followed by extubation to nasal continuous positive airway pressure (NCPAP) on subsequent mechanical ventilation (MV), when compared with NCPAP alone.
INTRODUCTION
Respiratory distress syndrome (RDS), resulting from a deficiency of pulmonary surfactant, is the most frequent clinical respiratory disorder in preterm infants. [1] [2] [3] [4] Intratracheal exogenous surfactant replacement therapy reduces mortality, air leak, and need for respiratory support in mechanically ventilated premature infants, with prophylactic or early surfactant therapy being superior to late rescue therapy in reducing mortality and respiratory morbidity. 3, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] By maintaining alveolar recruitment, early implementation of continuous positive airway pressure (CPAP) by itself, without surfactant therapy, has been shown to improve outcomes in infants with RDS. 5, 10, 18 However, strategies that use nasal continuous positive airway pressure (NCPAP) alone in mild-to-moderate RDS still result in up to 40 to 60% of patients requiring mechanical ventilation (MV). [19] [20] [21] Several clinical trials have attempted to draw upon the potential for synergy between early surfactant therapy and NCPAP in reducing the need for MV. Although early studies found that the need for MV in preterm infants with RDS was reduced when they were treated with surfactant provided by transient intubation and NCPAP compared with NCPAP alone, these trials were not blinded to treatment assignment and outcome, had relatively small study groups, and targeted infants <30 weeks' gestation with moderate-to-severe RDS. 5, 10 The purpose of this study was to assess the effectiveness of a single dose of intratracheal surfactant administered during the progression of RDS followed by rapid extubation and institution of NCPAP, using a blinded treatment intervention and outcome measure, in more mature preterm infants (Z29 weeks' gestation) with less severe RDS.
MATERIALS AND METHODS
The study was a controlled, randomized, and blinded trial comparing brief intubation for surfactant administration followed by institution of NCPAP with NCPAP alone. It was conducted in the neonatal intensive care unit (NICU) at the Golisano Children's Hospital at Strong between December 1995 and August 2002. The University of Rochester Research Subjects Review Board approved the study.
Subjects
All infants, both inborn and outborn, admitted to the NICU with a gestational age (GA) of 29 0/7 to 35 6/7 weeks with RDS by clinical and radiographic criteria and requiring supplemental oxygen by NCPAP, or by oxygen hood with imminent need for NCPAP, were eligible for the study. NCPAP was generally initiated in our unit whenever clinical signs of moderate respiratory distress were present. Infants could be enrolled between 30 minutes and 72 hours after birth, with the intent to enroll early in the course of RDS, as soon as a requirement for NCPAP became apparent. Initially, study entry criteria included inspired oxygen fraction (FiO 2 ) Z0.30. However, many potential subjects were missed due to intubation for respiratory compromise prior to meeting study criteria. The entry criteria were expanded in November 1998 to FiO 2 >0.21 so as better to target the intended population. RDS was defined as clinical respiratory distress in the presence of chest radiographic (CXR) evidence of lung field granularity, small lung volumes and air bronchograms. The clinical team caring for the infant initially interpreted the CXR. Final CXR diagnosis was determined from the attending pediatric radiologist's reading. Infants with pneumothorax, severe congenital malformations, and pulmonary hypoplasia were excluded. Infants who had previously required MV or had already received surfactant were also ineligible.
Study Procedures
Parental informed consent was obtained before enrollment. Prior to or concurrent with enrollment, arterial blood gas (ABG) analysis was performed. Abbott Laboratories (Columbus, OH) supplied the study surfactant (Survanta s , 200 mg/8 ml). Block randomization (block size of 10) was utilized. In order to blind the intervention and outcome, a syringe containing either the appropriate dose of surfactant or air was drawn up in the pharmacy and delivered in a manila envelope. Privacy screens were placed around the subject's bed and a study team not involved in that infant's care assumed management of the infant until study drug administration was complete.
Infants randomized to surfactant therapy and NCPAP (surfactant group) were intubated by the study team. Correct endotracheal tube placement was assessed clinically and/or with an end tidal CO 2 monitor. Surfactant (4 ml/kg) was administered in four divided aliquots, according to the manufacturer's instructions, followed by 3 to 5 minutes of hand ventilation. The infant was then extubated and started/restarted on NCPAP.
Infants randomized to NCPAP alone (control group) were not intubated and received no study drug or placebo. Infants already on NCPAP remained on NCPAP during the control intervention.
Infants not yet on NCPAP were begun on NCPAP before the close of the control intervention. To assure blinding, the study team remained behind the screens for as long as it would have taken to perform the surfactant group intervention (approximately 15 minutes).
In both groups, NCPAP was instituted with 1 to 1.5 cm length nasal prongs, using either a mechanical ventilator (Newport Breeze s , Newport Medical Instruments Inc., Newport Beach, CA or VIP Bird s , Bird Products Corporation, Palm Springs, CA) or a demand flow CPAP system (Aladdin s , Hamilton Medical Inc., Reno, NV). NCPAP was set at 6 cm (Newport Breeze, VIP Bird) or 4 cm (Aladdin) H 2 O at a flow of 8 l/minute. Care of the infant was then returned to the clinical team. At 1 to 2 hours after intervention, an ABG was performed. The attending neonatologist and clinical team made all further clinical decisions, including institution of MV and/or surfactant treatment, based on uniform criteria in place in our NICU. The criteria for intubation and MV included FiO 2 requirement >0.30 and rising, CO 2 retention (PaCO 2 >50 to 55 torr), apnea (>20 seconds), and/or moderate-to-severe retractions. The criteria for subsequent clinical surfactant doses (drawn from a clinical stock of Survanta s ) were need for MV with FiO 2 >0.30 and PaO 2 r80 torr at Z6 hours from last dose. It was not necessary to wait 6 hours from study treatment (either surfactant or control) to administer the first subsequent dose of surfactant if other clinical criteria were met.
Definitions
Enrollment FiO 2 and treatment FiO 2 were defined as FiO 2 at the times of the pretreatment blood gas and study intervention, respectively. Bronchopulmonary dysplasia (BPD) was defined according to the 2001 NIH Consensus definition. 22 
Analysis
The primary outcome of the study was requirement for MV. Predetermined secondary outcomes were duration of assisted ventilation, duration of O 2 therapy, peak FiO 2 , and need for subsequent doses of surfactant.
We estimated that 103 subjects per group would be required to demonstrate a reduction in need for MV from 70% (the historical proportion of RDS infants in our NICU requiring supplemental O 2 who went on to receive MV) to 50%, with a power of 80% and a significance level of 5% (two-sided). The data were analyzed by intention to treat. Continuous data were analyzed using the Student's t-test. Categorical data were analyzed by Fisher's exact test or Pearson's w 2 , as appropriate. The Mann-Whitney U-test was used to compare ordinal or non-parametric data.
RESULTS
Accrual was significantly slower than projected. As a result, enrollment was closed (prior to any data analysis) following the first scheduled interim evaluation. In all, 175 infants were eligible for study entry. Of these, 105 subjects (53 control, 52 surfactant) were enrolled, 23 of these prior to the change in entry criteria to FiO 2 >0.21 (see also Supplementary Information S1).
Study groups were similar with regard to baseline characteristics (Tables 1 and 2 ). One control subject had a retrospectively determined best GA estimate of 36.1 weeks. Pre-eclampsia was slightly over-represented in the surfactant group. Three infants from the control group and two infants from the surfactant group had a normal CXR at final reading, although they were felt clinically to have RDS. One infant from the surfactant group was recognized after study enrollment to have congenital diaphragmatic hernia (CDH) in addition to RDS. All subjects, except one in the control group, received study treatment by 48 hours of age. A ventilator was used to administer NCPAP in 92 subjects (45 control, 47 surfactant) and a demand flow system was used in 13 subjects (eight control, five surfactant). There were no differences in outcome by type of NCPAP.
The need for subsequent MV was reduced from 70% in the control group to 50% in the surfactant group ( p ¼ 0.04) ( Table 3) . Surfactant group infants had a lower FiO 2 requirement for 5 hours post-treatment than control infants (Figure 1 ). Median duration of O 2 therapy and mean peak FiO 2 were similar between groups. Among infants who required subsequent MV, the duration of MV was not significantly altered by study treatment. Control subjects were more likely to need at least one dose of subsequent surfactant, and received a higher median number of doses of subsequent surfactant. If all doses of surfactant were considered, including the study dose, the numbers of doses were similar between groups (control: 67 total doses, surfactant: 77 total doses). The median time to receiving any dose of surfactant (including study dose) was 16.5 hours (range 3.7 to 53 hours) in the control group and 6.5 hours (range 1.6 to 36.3 hours) in the surfactant group ( p ¼ 0.0001).
Five protocol violations, involving either the assigned treatment not being given (N ¼ 3) or the wrong treatment given (N ¼ 2), were identified. Excluding the one subject with CDH and assessing the actual treatment received (as opposed to treatment intended) did not change the need for MV (no study surfactant 70%, study surfactant 49%; p ¼ 0.03). The primary outcome was also assessed for subjects enrolled before and after the change in study entry criteria. No differences in MV rates were found between study groups in the initial group of subjects (control 7/11 [64%], surfactant 8/12 [67%]; p ¼ 1.0). After the study entry criteria change, 30/42 (71%) control group infants and 18/40 (45%) surfactant group infants required MV (p ¼ 0.015). Even after the entry criteria were changed, the mean FiO 2 at the time of enrollment was 0.41, and did not differ between groups.
Among infants who required MV, time from study intervention to MV tended to be longer in the surfactant group (Table 3) . The primary reasons for subsequent MV were respiratory compromise (90%) and apnea (6%), without differences between the groups. In all, 46 (26 control and 20 surfactant) of the 63 subjects who required MV had an ABG within 4 hours prior to initiation of MV. At that time, there was no difference between groups in median alveolar-to-arterial oxygen (a/A) ratio (control 0.25 [range 0.08 to 0.6], surfactant 0.33 [range 0.1 to Table 3 ). The overall incidence of BPD was low (2%). No adverse events were seen during the administration of any dose of surfactant (including the study dose), regardless of time from study dose. w Two subjects in the surfactant group did not receive study treatment. z Among those with arterial blood gas available. An ABG following study treatment was not obtained in 10 control subjects and 10 surfactant subjects. Italic p-values denote statistically significant results. y Death at 168 days of age, unrelated to study treatment. See also Supplementary Information S2 and S3.
DISCUSSION
The 20% absolute reduction in MV rates observed in our study is similar to the effect size (10 to 40%) observed in other studies of NCPAP and surfactant, which evaluated infants of widely varying GAs (25 to 35 weeks) and birthweights (1250 to 2500 g), with entry criteria varying from mild to severe RDS. 5, 6, [19] [20] [21] A recent systematic review that included data from several of these studies, 5, 19, 20 as well as preliminary results from our study, 23 concluded that ''infants with RDS treated with early surfactant replacement therapy and NCPAP are less likely to need mechanical ventilation than are infants treated with NCPAP and later surfactant therapy''. 24 However, overall surfactant use was higher with an early surfactant strategy. Few of the studies cited directly measured outcomes such as air leak, patent ductus arteriosus or chronic lung disease; no significant effect on these factors was found.
Our study differed from previous studies in that the patient population targeted was more mature than those that have typically been evaluated. The study was designed to enroll infants with mild-to-moderate RDS early in the disease process. Enrollment a/A ratios and FiO 2 suggested that our final study population did indeed have mild-to-moderate severity of RDS at randomization, as was intended. 5, 6 The study also differed from earlier studies of surfactant and NCPAP in that study group assignment was masked.
Other studies reported a high incidence of apnea as a cause for MV. 5, 6, 20 However, we found that respiratory decompensation, based primarily on clinical symptoms of distress rather than elevated PaCO 2 levels, was the most likely reason for intubation in our study. Infants in our study were placed on MV at a/A ratios consistent with moderate RDS, but higher than those prompting MV in several other studies that used physiologic intubation criteria. 5, 6 Similar to findings in other studies, we found improvement in several short-term respiratory parameters in subjects who received surfactant via transient intubation. 5, 8, 10 Study surfactant also appeared to delay MV among those infants who went on to require MV. However, most long-term respiratory morbidities and outcomes remained unaffected, perhaps reflecting the overall good health of these infants. The relatively low rate of antenatal glucocorticoid use in our study subjects may reflect a selection bias that screened out infants with good antenatal glucocorticoid effect.
There was a trend toward fewer pneumothoraces in the surfactant group. This trend has also been seen in a number of other studies. 5, 6, 20 Collectively, these data suggest a decreased incidence of pneumothorax in infants with RDS who are treated with early surfactant via transient intubation, as opposed to those expectantly managed.
This study has some limitations. Subjects in the surfactant group received a brief period of hand ventilation following surfactant administration, which could have increased alveolar recruitment. However, barotrauma is a possible adverse effect of hand ventilation. The overall effect of the hand ventilation is difficult to separate out from the effect of surfactant therapy. The sample size was relatively small, although larger than those of several similar studies. The sample size reduced the power to find smaller differences that may have existed between study groups in secondary outcomes such as pneumothorax and post-treatment a/A ratio, which approached significance. The study used prevailing clinical criteria for MV, which were often based on physical evaluation of the infant. However, by masking treatment status from the clinical team, the application of this intervention was decided upon in a blinded manner. This approach may have led to some imprecision (random error) in measurement of the outcome, but was unlikely to lead to bias (systematic error).
In summary, this study of infants 29 to 35 weeks' gestation with mild-to-moderate RDS found that transient intubation for surfactant therapy followed by NCPAP for infants with RDS requiring NCPAP is effective in reducing the need for MV, when compared with NCPAP alone. Five infants would need to be treated to prevent one infant from requiring MV (number needed to treat ¼ 5). Our intervention did not decrease the overall use of surfactant, nor did it affect the already low incidence of BPD in this population. Since the resources involved in caring for infants requiring MV are expensive, transient intubation for surfactant treatment in the older premature infant may be particularly valuable in NICUs where resources are limited. and surfactant (dark squares) group infants, immediately before study treatment (pre) and hourly for 6 hours after study treatment. Surfactant group subjects had lower FiO 2 than controls for up to 5 hours following treatment. (*p ¼ 0.015, **p<0.01 by Student's t-test.)
